nicardipine ๐Ÿถ Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
calcium channel blockers, nifedipine derivatives 1909 55985-32-5

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • nicardipine
  • (+/-)-Nicardipine
  • perpidine
  • nicardipine hydrochloride
  • nicardipine HCl
A potent calcium channel blockader with marked vasodilator action. It has antihypertensive properties and is effective in the treatment of angina and coronary spasms without showing cardiodepressant effects. It has also been used in the treatment of asthma and enhances the action of specific antineoplastic agents.
  • Molecular weight: 479.53
  • Formula: C26H29N3O6
  • CLOGP: 5.23
  • LIPINSKI: 1
  • HAC: 9
  • HDO: 1
  • TPSA: 111.01
  • ALOGS: -5.29
  • ROTB: 11

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
90 mg O
90 mg P

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 1 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 7.90 mg/mL Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 0 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 4.17 ยตM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 23 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 1 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 11 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.01 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 4.10 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
Dec. 21, 1988 FDA CHIESI USA INC

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Cerebral vasoconstriction 140.58 23.99 31 6250 961 50597882
Premature delivery 121.20 23.99 59 6222 23604 50575239
Hyponatraemia 120.88 23.99 98 6183 96041 50502802
Acute kidney injury 117.99 23.99 143 6138 227915 50370928
Hepatocellular injury 90.52 23.99 50 6231 25897 50572946
Posterior reversible encephalopathy syndrome 84.86 23.99 40 6241 14888 50583955
Hyperkalaemia 82.36 23.99 59 6222 48030 50550813
Acute motor-sensory axonal neuropathy 81.72 23.99 16 6265 272 50598571
Acute pulmonary oedema 79.63 23.99 31 6250 7236 50591607
Eosinophilia 79.27 23.99 41 6240 18611 50580232
Cerebral haemorrhage 67.59 23.99 42 6239 27010 50571833
Cholestasis 64.89 23.99 40 6241 25361 50573482
Hypotension 64.21 23.99 109 6172 235360 50363483
Low birth weight baby 64.12 23.99 25 6256 5856 50592987
Exposure during pregnancy 60.92 23.99 75 6206 120940 50477903
Bradycardia 57.31 23.99 54 6227 64372 50534471
Lactic acidosis 52.71 23.99 39 6242 33316 50565527
Hyperlactacidaemia 51.85 23.99 17 6264 2416 50596427
Hemivertebra 48.01 23.99 9 6272 120 50598723
Acute generalised exanthematous pustulosis 47.88 23.99 23 6258 8915 50589928
Orthostatic hypotension 47.77 23.99 35 6246 29446 50569397
Haemangioma congenital 47.45 23.99 11 6270 428 50598415
Premature baby 47.14 23.99 29 6252 18308 50580535
Haemorrhagic transformation stroke 46.28 23.99 13 6268 1096 50597747
Maternal exposure during pregnancy 46.19 23.99 76 6205 159702 50439141
Fall 45.05 23.99 116 6165 334816 50264027
Drug interaction 44.85 23.99 85 6196 199536 50399307
Hypokalaemia 43.38 23.99 54 6227 87938 50510905
Purpura 42.71 23.99 22 6259 9889 50588954
Drug reaction with eosinophilia and systemic symptoms 42.15 23.99 32 6249 28392 50570451
Thrombocytopenia 41.37 23.99 64 6217 127609 50471234
Fatigue 40.12 23.99 19 6262 707582 49891261
Congenital choroid plexus cyst 39.72 23.99 9 6272 316 50598527
Rash maculo-papular 39.52 23.99 30 6251 26611 50572232
Paradoxical drug reaction 37.98 23.99 15 6266 3632 50595211
Ischaemic stroke 37.90 23.99 24 6257 15924 50582919
Premature labour 36.96 23.99 21 6260 11455 50587388
Subarachnoid haemorrhage 35.46 23.99 20 6261 10756 50588087
Foetal growth restriction 35.33 23.99 17 6264 6610 50592233
Pain 35.22 23.99 14 6267 578889 50019954
Hepatic cytolysis 34.95 23.99 18 6263 8085 50590758
Haematoma 33.88 23.99 29 6252 30481 50568362
Rhabdomyolysis 33.32 23.99 32 6249 38995 50559848
Arthralgia 33.27 23.99 7 6274 438695 50160148
Metabolic encephalopathy 33.07 23.99 15 6266 5106 50593737
Anaphylactic shock 32.81 23.99 24 6257 20131 50578712
Renal failure 32.51 23.99 52 6229 106581 50492262
Patent ductus arteriosus 30.53 23.99 13 6268 3807 50595036
Tumour rupture 30.42 23.99 6 6275 106 50598737
Cutaneous lupus erythematosus 28.87 23.99 11 6270 2420 50596423
Foetal exposure during pregnancy 28.34 23.99 25 6256 27334 50571509
Respiratory distress 27.93 23.99 26 6255 30463 50568380
Hypertrophic cardiomyopathy 27.06 23.99 9 6272 1336 50597507
Toxic skin eruption 26.90 23.99 17 6264 11234 50587609
Altered state of consciousness 26.74 23.99 22 6259 21888 50576955
Haemodynamic instability 26.69 23.99 15 6266 8009 50590834
Pre-eclampsia 26.66 23.99 15 6266 8029 50590814
Acquired haemophilia 26.26 23.99 8 6273 895 50597948
Intra-abdominal haematoma 25.77 23.99 9 6272 1548 50597295
Mixed liver injury 25.14 23.99 11 6270 3440 50595403
Wrong patient received product 25.00 23.99 9 6272 1691 50597152
Sinus bradycardia 24.45 23.99 17 6264 13166 50585677
Metabolic acidosis 24.39 23.99 27 6254 38798 50560045

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Cerebral vasoconstriction 108.75 20.15 20 4380 196 29569931
Blood lactic acid 87.51 20.15 18 4382 328 29569799
Foetal disorder 83.08 20.15 20 4380 763 29569364
Neutropenia neonatal 76.02 20.15 18 4382 639 29569488
Acute kidney injury 70.30 20.15 134 4266 265133 29304994
Premature baby 69.78 20.15 39 4361 17241 29552886
Ureteric compression 67.38 20.15 13 4387 168 29569959
Low birth weight baby 56.95 20.15 25 4375 6583 29563544
Cerebral haemorrhage 55.04 20.15 42 4358 31384 29538743
Haematoma muscle 45.85 20.15 13 4387 944 29569183
Antiphospholipid antibodies positive 44.51 20.15 10 4390 280 29569847
Pyelocaliectasis 43.95 20.15 13 4387 1096 29569031
Foetal exposure during pregnancy 36.05 20.15 34 4366 33833 29536294
Cholestasis 35.96 20.15 29 4371 23433 29546694
Phlebitis deep 32.14 20.15 5 4395 15 29570112
Drug reaction with eosinophilia and systemic symptoms 31.52 20.15 29 4371 27963 29542164
Rash maculo-papular 30.98 20.15 27 4373 24262 29545865
Extravasation 30.94 20.15 11 4389 1661 29568466
Haemorrhagic transformation stroke 29.61 20.15 10 4390 1296 29568831
Bradycardia 29.16 20.15 42 4358 65587 29504540
Paradoxical drug reaction 29.01 20.15 12 4388 2729 29567398
Eosinophilia 29.00 20.15 25 4375 22136 29547991
Hepatic cytolysis 28.75 20.15 17 4383 8330 29561797
Thalamus haemorrhage 28.70 20.15 9 4391 923 29569204
Hyperkalaemia 28.32 20.15 40 4360 61352 29508775
Kidney small 26.74 20.15 5 4395 54 29570073
Brain herniation 25.76 20.15 12 4388 3621 29566506
Ventricular tachycardia 22.75 20.15 22 4378 22552 29547575
Haemorrhagic cerebral infarction 22.15 20.15 7 4393 736 29569391
Mixed liver injury 21.77 20.15 9 4391 2042 29568085
Respiratory gas exchange disorder 21.16 20.15 6 4394 435 29569692
Injection site oedema 20.81 20.15 5 4395 189 29569938
Blood fibrinogen decreased 20.70 20.15 7 4393 911 29569216
Fatigue 20.28 20.15 11 4389 316810 29253317

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Cerebral vasoconstriction 233.35 19.31 51 10214 1171 64487296
Acute kidney injury 166.27 19.31 273 9992 448967 64039500
Cerebral haemorrhage 106.73 19.31 78 10187 51012 64437455
Eosinophilia 97.84 19.31 66 10199 38010 64450457
Cholestasis 92.57 19.31 68 10197 44804 64443663
Hyperkalaemia 91.85 19.31 96 10169 101033 64387434
Hepatocellular injury 89.83 19.31 67 10198 45168 64443299
Hyponatraemia 89.51 19.31 114 10151 148225 64340242
Blood lactic acid 81.06 19.31 18 10247 445 64488022
Acute motor-sensory axonal neuropathy 72.03 19.31 16 10249 396 64488071
Bradycardia 69.93 19.31 90 10175 118129 64370338
Haemorrhagic transformation stroke 67.68 19.31 22 10243 2367 64486100
Ureteric compression 66.35 19.31 13 10252 170 64488297
Posterior reversible encephalopathy syndrome 64.31 19.31 42 10223 22904 64465563
Paradoxical drug reaction 63.71 19.31 27 10238 6093 64482374
Hepatic cytolysis 63.56 19.31 35 10230 14014 64474453
Drug reaction with eosinophilia and systemic symptoms 63.18 19.31 59 10206 54158 64434309
Rash maculo-papular 60.30 19.31 54 10211 46972 64441495
Acute pulmonary oedema 55.45 19.31 31 10234 12778 64475689
Fatigue 51.02 19.31 28 10237 748702 63739765
Hypotension 49.67 19.31 153 10112 380821 64107646
Premature delivery 47.19 19.31 32 10233 18557 64469910
Pyelocaliectasis 46.68 19.31 13 10252 825 64487642
Lactic acidosis 46.47 19.31 53 10212 61357 64427110
Ischaemic stroke 44.64 19.31 37 10228 28998 64459469
Hypokalaemia 44.61 19.31 74 10191 121829 64366638
Purpura 42.15 19.31 29 10236 17217 64471250
Haematoma 42.10 19.31 44 10221 46206 64442261
Mixed liver injury 40.43 19.31 19 10246 5462 64483005
Acute generalised exanthematous pustulosis 40.04 19.31 26 10239 14032 64474435
Altered state of consciousness 39.88 19.31 39 10226 37863 64450604
Exposure during pregnancy 39.55 19.31 55 10210 77620 64410847
Hyperlactacidaemia 39.50 19.31 18 10247 4826 64483641
Renal failure 39.03 19.31 88 10177 181600 64306867
Pain 38.67 19.31 20 10245 553491 63934976
Haematoma muscle 36.94 19.31 13 10252 1780 64486687
Orthostatic hypotension 36.48 19.31 41 10224 46697 64441770
Fall 35.03 19.31 145 10120 416681 64071786
Thrombocytopenia 34.98 19.31 96 10169 223705 64264762
Subarachnoid haemorrhage 33.68 19.31 26 10239 18412 64470055
Respiratory distress 32.73 19.31 41 10224 52290 64436177
Phlebitis deep 32.33 19.31 5 10260 13 64488454
Premature labour 31.78 19.31 18 10247 7602 64480865
Antiphospholipid antibodies positive 30.97 19.31 9 10256 666 64487801
Haemorrhagic cerebral infarction 28.89 19.31 10 10255 1304 64487163
Brain herniation 28.79 19.31 16 10249 6517 64481950
Cardiac arrest 28.05 19.31 70 10195 153994 64334473
Thrombotic microangiopathy 27.23 19.31 22 10243 16633 64471834
Thalamus haemorrhage 26.85 19.31 10 10255 1609 64486858
Pulmonary hypoplasia 26.40 19.31 5 10260 54 64488413
Anaphylactic shock 26.08 19.31 28 10237 30300 64458167
Drug interaction 25.84 19.31 120 10145 361963 64126504
Confusional state 25.24 19.31 95 10170 261049 64227418
Dizziness 25.23 19.31 19 10246 430144 64058323
Cutaneous lupus erythematosus 25.17 19.31 11 10254 2671 64485796
Haemodynamic instability 25.02 19.31 20 10245 14892 64473575
Vasoplegia syndrome 24.84 19.31 11 10254 2756 64485711
Maternal exposure during pregnancy 24.66 19.31 50 10215 95834 64392633
Pre-eclampsia 24.06 19.31 14 10251 6217 64482250
Metabolic encephalopathy 23.24 19.31 15 10250 8010 64480457
Acquired haemophilia 23.24 19.31 9 10256 1611 64486856
Arthralgia 22.92 19.31 22 10243 442238 64046229
Foetal growth restriction 22.66 19.31 9 10256 1721 64486746
Rhabdomyolysis 22.60 19.31 47 10218 91679 64396788
Toxic skin eruption 22.47 19.31 21 10244 19263 64469204
Agranulocytosis 22.40 19.31 29 10236 38200 64450267
Tumour rupture 21.95 19.31 6 10259 355 64488112
Hypertrophic cardiomyopathy 21.91 19.31 9 10256 1877 64486590
Brain contusion 21.82 19.31 8 10257 1231 64487236
Ventricular tachycardia 21.67 19.31 27 10238 34238 64454229
Peripheral swelling 20.85 19.31 4 10261 209149 64279318
Headache 20.46 19.31 33 10232 529434 63959033
Weight decreased 20.39 19.31 10 10255 285729 64202738
Porphyria 20.19 19.31 5 10260 200 64488267
Enterobacter sepsis 19.86 19.31 7 10258 962 64487505
Cerebral haematoma 19.75 19.31 13 10252 7172 64481295
Intra-abdominal haematoma 19.54 19.31 9 10256 2470 64485997
Gestational hypertension 19.45 19.31 8 10257 1673 64486794
Metabolic acidosis 19.44 19.31 38 10227 70920 64417547

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC C08CA04 CARDIOVASCULAR SYSTEM
CALCIUM CHANNEL BLOCKERS
SELECTIVE CALCIUM CHANNEL BLOCKERS WITH MAINLY VASCULAR EFFECTS
Dihydropyridine derivatives
FDA CS M0006414 Dihydropyridines
FDA MoA N0000000069 Calcium Channel Antagonists
FDA EPC N0000175421 Dihydropyridine Calcium Channel Blocker
MeSH PA D000959 Antihypertensive Agents
MeSH PA D002121 Calcium Channel Blockers
MeSH PA D000077264 Calcium-Regulating Hormones and Agents
MeSH PA D002317 Cardiovascular Agents
MeSH PA D049990 Membrane Transport Modulators
MeSH PA D014665 Vasodilator Agents
CHEBI has role CHEBI:35620 vasodilator agents
CHEBI has role CHEBI:35674 antihypertensive drugs
CHEBI has role CHEBI:38215 calcium channel blockers
CHEBI has role CHEBI:88230 autophagy inhibitors
CHEBI has role CHEBI:176497 geroprotectors
FDA MoA N0000182137 Cytochrome P450 2D6 Inhibitors
FDA MoA N0000182140 Cytochrome P450 2C19 Inhibitors
FDA MoA N0000182141 Cytochrome P450 3A4 Inhibitors
FDA MoA N0000187062 Cytochrome P450 2C8 Inhibitors

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Hypertensive disorder indication 38341003 DOID:10763
Angina pectoris indication 194828000
Prinzmetal angina off-label use 87343002
Raynaud's phenomenon off-label use 266261006
Portal hypertension contraindication 34742003 DOID:10762
Low blood pressure contraindication 45007003
Chronic heart failure contraindication 48447003
Chronic idiopathic constipation contraindication 82934008
Impaired renal function disorder contraindication 197663003
Disease of liver contraindication 235856003 DOID:409
Cerebral hemorrhage contraindication 274100004
Cerebral infarction contraindication 432504007 DOID:3526
Severe Aortic Valve Stenosis contraindication




๐Ÿถ Veterinary Drug Use

None

๐Ÿถ Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 7.02 Basic
pKa2 2.37 Basic

Orange Book patent data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRoutePatent numberPatent expiration datePatent use
20MG/200ML (0.1MG/ML) CARDENE IN 0.86% SODIUM CHLORIDE IN PLASTIC CONTAINER CHIESI N019734 July 31, 2008 RX INJECTABLE INTRAVENOUS 7659291 April 18, 2027 METHOD FOR TREATING ACUTE ELEVATIONS OF BLOOD PRESSURE IN HUMAN SUBJECT IN NEED THEREOF
20MG/200ML (0.1MG/ML) CARDENE IN 4.8% DEXTROSE IN PLASTIC CONTAINER CHIESI N019734 July 31, 2008 RX INJECTABLE INTRAVENOUS 7659291 April 18, 2027 METHOD FOR TREATING ACUTE ELEVATIONS OF BLOOD PRESSURE IN HUMAN SUBJECT IN NEED THEREOF
20MG/200ML (0.1MG/ML) CARDENE IN 0.86% SODIUM CHLORIDE IN PLASTIC CONTAINER CHIESI N019734 July 31, 2008 RX INJECTABLE INTRAVENOUS 8455524 April 18, 2027 METHOD FOR TREATING ACUTE ELEVATIONS OF BLOOD PRESSURE IN HUMAN SUBJECT IN NEED THEREOF
20MG/200ML (0.1MG/ML) CARDENE IN 4.8% DEXTROSE IN PLASTIC CONTAINER CHIESI N019734 July 31, 2008 RX INJECTABLE INTRAVENOUS 8455524 April 18, 2027 METHOD FOR TREATING ACUTE ELEVATIONS OF BLOOD PRESSURE IN HUMAN SUBJECT IN NEED THEREOF
40MG/200ML (0.2MG/ML) CARDENE IN 0.83% SODIUM CHLORIDE IN PLASTIC CONTAINER CHIESI N019734 Nov. 7, 2008 RX INJECTABLE INTRAVENOUS 7659291 April 18, 2027 METHOD FOR TREATING ACUTE ELEVATIONS OF BLOOD PRESSURE IN HUMAN SUBJECT IN NEED THEREOF
40MG/200ML (0.2MG/ML) CARDENE IN 5.0% DEXTROSE IN PLASTIC CONTAINER CHIESI N019734 Nov. 7, 2008 DISCN INJECTABLE INTRAVENOUS 7659291 April 18, 2027 METHOD FOR TREATING ACUTE ELEVATIONS OF BLOOD PRESSURE IN HUMAN SUBJECT IN NEED THEREOF
40MG/200ML (0.2MG/ML) CARDENE IN 0.83% SODIUM CHLORIDE IN PLASTIC CONTAINER CHIESI N019734 Nov. 7, 2008 RX INJECTABLE INTRAVENOUS 8455524 April 18, 2027 METHOD FOR TREATING ACUTE ELEVATIONS OF BLOOD PRESSURE IN HUMAN SUBJECT IN NEED THEREOF
40MG/200ML (0.2MG/ML) CARDENE IN 5.0% DEXTROSE IN PLASTIC CONTAINER CHIESI N019734 Nov. 7, 2008 DISCN INJECTABLE INTRAVENOUS 8455524 April 18, 2027 METHOD FOR TREATING ACUTE ELEVATIONS OF BLOOD PRESSURE IN HUMAN SUBJECT IN NEED THEREOF

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Voltage-gated L-type calcium channel Ion channel BLOCKER CHEMBL CHEMBL
Multidrug resistance protein 1 Transporter IC50 5.32 CHEMBL
Adenosine receptor A3 GPCR Ki 5.49 CHEMBL
Nuclear receptor subfamily 1 group I member 2 Nuclear hormone receptor WOMBAT-PK
ATP-binding cassette sub-family G member 2 Transporter IC50 4.78 CHEMBL
Cytochrome P450 2C9 Enzyme IC50 6.55 WOMBAT-PK
Voltage-dependent T-type calcium channel subunit alpha-1H Ion channel Ki 5.55 WOMBAT-PK
Malate dehydrogenase cytoplasmic Enzyme IC50 4.30 CHEMBL
Cytochrome P450 3A4 Enzyme IC50 6.38 WOMBAT-PK
Beta-lactamase Enzyme IC50 4.70 CHEMBL
Adenosine receptor A1 GPCR Ki 4.71 CHEMBL
Adenosine receptor A2a GPCR Ki 4.20 CHEMBL
Adenosine receptor A3 GPCR Ki 4.96 CHEMBL
Equilibrative nucleoside transporter 1 Transporter Ki 5.27 CHEMBL
Quinolone resistance protein NorA Transporter IC50 4.64 CHEMBL
Adrenergic receptor alpha-2 GPCR IC50 5.85 CHEMBL
Adrenergic receptor alpha-1 GPCR IC50 5.44 CHEMBL
Voltage-gated L-type calcium channel Ion channel Ki 9.08 CHEMBL
Potassium voltage-gated channel subfamily A member 4 Ion channel BLOCKER IC50 6.10 IUPHAR

External reference:

IDSource
4019858 VUID
N0000147944 NUI
D00617 KEGG_DRUG
54527-84-3 SECONDARY_CAS_RN
4019350 VANDF
4019858 VANDF
C0028005 UMLSCUI
CHEBI:7550 CHEBI
CHEMBL1484 ChEMBL_ID
CHEMBL1200326 ChEMBL_ID
D009529 MESH_DESCRIPTOR_UI
DB00622 DRUGBANK_ID
2559 IUPHAR_LIGAND_ID
4745 INN_ID
CZ5312222S UNII
4474 PUBCHEM_CID
235230 RXNORM
2278 MMSL
5171 MMSL
d00315 MMSL
000712 NDDF
004518 NDDF
108526002 SNOMEDCT_US
108527006 SNOMEDCT_US
372502001 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Nicardipine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0143-9542 INJECTION 2.50 mg INTRAVENOUS NDA 26 sections
Nicardipine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0143-9542 INJECTION 2.50 mg INTRAVENOUS NDA 26 sections
Nicardipine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0143-9593 INJECTION 2.50 mg INTRAVENOUS NDA 26 sections
Nicardipine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0143-9633 INJECTION 0.20 mg INTRAVENOUS NDA 27 sections
Nicardipine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0143-9633 INJECTION 0.20 mg INTRAVENOUS NDA 27 sections
Nicardipine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0143-9634 INJECTION 0.10 mg INTRAVENOUS NDA 27 sections
Nicardipine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0143-9634 INJECTION 0.10 mg INTRAVENOUS NDA 27 sections
Nicardipine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0143-9689 INJECTION 25 mg INTRAVENOUS NDA 27 sections
Nicardipine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0143-9689 INJECTION 25 mg INTRAVENOUS NDA 27 sections
Nicardipine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0378-1020 CAPSULE 20 mg ORAL ANDA 22 sections
Nicardipine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0378-1430 CAPSULE 30 mg ORAL ANDA 22 sections
Nicardipine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0517-0735 INJECTION, SOLUTION 2.50 mg INTRAVENOUS ANDA 26 sections
Nicardipine Hydrochloride Human Prescription Drug Label 1 0781-3204 INJECTION 2.50 mg INTRAVENOUS ANDA 12 sections
Nicardipine Hydrochloride Human Prescription Drug Label 1 0781-9324 INJECTION 2.50 mg INTRAVENOUS ANDA 12 sections
Cardene IV HUMAN PRESCRIPTION DRUG LABEL 1 10122-313 INJECTION, SOLUTION 0.10 mg INTRAVENOUS NDA 23 sections
Cardene IV HUMAN PRESCRIPTION DRUG LABEL 1 10122-314 INJECTION, SOLUTION 0.10 mg INTRAVENOUS NDA 23 sections
Cardene IV HUMAN PRESCRIPTION DRUG LABEL 1 10122-325 INJECTION, SOLUTION 0.20 mg INTRAVENOUS NDA 23 sections
Nicardipine Hydrochloride Human Prescription Drug Label 1 14593-124 INJECTION 2.50 mg INTRAVENOUS ANDA 12 sections
Nicardipine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 24658-750 CAPSULE 20 mg ORAL ANDA 19 sections
Nicardipine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 24658-751 CAPSULE 30 mg ORAL ANDA 19 sections
Nicardipine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 40042-047 INJECTION, SOLUTION 2.50 mg INTRAVENOUS ANDA 20 sections
Nicardipine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 42806-501 CAPSULE 20 mg ORAL ANDA 19 sections
Nicardipine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 42806-502 CAPSULE 30 mg ORAL ANDA 19 sections
CARDENE IV HUMAN PRESCRIPTION DRUG LABEL 1 43066-009 INJECTION, SOLUTION 0.10 mg INTRAVENOUS NDA 24 sections
CARDENE IV HUMAN PRESCRIPTION DRUG LABEL 1 43066-009 INJECTION, SOLUTION 0.10 mg INTRAVENOUS NDA 24 sections
CARDENE IV HUMAN PRESCRIPTION DRUG LABEL 1 43066-016 INJECTION, SOLUTION 0.20 mg INTRAVENOUS NDA 24 sections
CARDENE IV HUMAN PRESCRIPTION DRUG LABEL 1 43066-016 INJECTION, SOLUTION 0.20 mg INTRAVENOUS NDA 24 sections
Cardene IV HUMAN PRESCRIPTION DRUG LABEL 1 43066-021 INJECTION, SOLUTION 0.10 mg INTRAVENOUS NDA 24 sections
Cardene IV HUMAN PRESCRIPTION DRUG LABEL 1 43066-021 INJECTION, SOLUTION 0.10 mg INTRAVENOUS NDA 24 sections
Cardene IV HUMAN PRESCRIPTION DRUG LABEL 1 43066-024 INJECTION, SOLUTION 0.20 mg INTRAVENOUS NDA 24 sections